{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Non-small+Cell+Lung+Cancer&page=44",
    "query": {
      "condition": "Stage IV Non-small Cell Lung Cancer",
      "page": 44
    },
    "page_size": 10
  },
  "pagination": {
    "page": 44,
    "page_size": 10,
    "total_count": 1169,
    "total_pages": 117,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Non-small+Cell+Lung+Cancer&page=45&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Non-small+Cell+Lung+Cancer&page=43&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T04:44:21.672Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00138203",
      "title": "Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Non-small Cell Lung Cancer",
        "Stage IIIB Non-small Cell Lung Cancer",
        "Stage IV Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "vorinostat",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2005-06",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2018-01-30",
      "last_synced_at": "2026-10-19T04:44:21.672Z",
      "location_count": 5,
      "location_summary": "Green Bay, Wisconsin • La Crosse, Wisconsin • Madison, Wisconsin + 1 more",
      "locations": [
        {
          "city": "Green Bay",
          "state": "Wisconsin"
        },
        {
          "city": "La Crosse",
          "state": "Wisconsin"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        },
        {
          "city": "Manitowoc",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00138203"
    },
    {
      "nct_id": "NCT00063895",
      "title": "Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Non-small Cell Lung Cancer",
        "Recurrent Ovarian Epithelial Cancer",
        "Recurrent Squamous Cell Carcinoma of the Hypopharynx",
        "Recurrent Squamous Cell Carcinoma of the Larynx",
        "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Recurrent Squamous Cell Carcinoma of the Nasopharynx",
        "Recurrent Squamous Cell Carcinoma of the Oropharynx",
        "Stage III Squamous Cell Carcinoma of the Hypopharynx",
        "Stage III Squamous Cell Carcinoma of the Larynx",
        "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage III Squamous Cell Carcinoma of the Nasopharynx",
        "Stage III Squamous Cell Carcinoma of the Oropharynx",
        "Stage IIIA Non-small Cell Lung Cancer",
        "Stage IIIA Ovarian Epithelial Cancer",
        "Stage IIIB Non-small Cell Lung Cancer",
        "Stage IIIB Ovarian Epithelial Cancer",
        "Stage IIIC Ovarian Epithelial Cancer",
        "Stage IV Non-small Cell Lung Cancer",
        "Stage IV Ovarian Epithelial Cancer",
        "Stage IV Squamous Cell Carcinoma of the Hypopharynx",
        "Stage IV Squamous Cell Carcinoma of the Nasopharynx",
        "Stage IVA Squamous Cell Carcinoma of the Larynx",
        "Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IVA Squamous Cell Carcinoma of the Oropharynx",
        "Stage IVB Squamous Cell Carcinoma of the Larynx",
        "Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IVB Squamous Cell Carcinoma of the Oropharynx",
        "Stage IVC Squamous Cell Carcinoma of the Larynx",
        "Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IVC Squamous Cell Carcinoma of the Oropharynx"
      ],
      "interventions": [
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "pharmacogenomic studies",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2003-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-09",
      "last_synced_at": "2026-10-19T04:44:21.672Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00063895"
    },
    {
      "nct_id": "NCT02642939",
      "title": "Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer (NSCLC)"
      ],
      "interventions": [
        {
          "name": "Mifepristone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Check, Jerome H., M.D., Ph.D.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2015-12",
      "completion_date": "2020-10-15",
      "has_results": false,
      "last_update_posted_date": "2020-10-19",
      "last_synced_at": "2026-10-19T04:44:21.672Z",
      "location_count": 1,
      "location_summary": "Melrose Park, Pennsylvania",
      "locations": [
        {
          "city": "Melrose Park",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02642939"
    },
    {
      "nct_id": "NCT05633602",
      "title": "Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Recurrent Lung Non-Small Cell Carcinoma",
        "Stage IV Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ramucirumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 838,
      "start_date": "2023-03-14",
      "completion_date": "2028-03-15",
      "has_results": false,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-10-19T04:44:21.672Z",
      "location_count": 566,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 442 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05633602"
    },
    {
      "nct_id": "NCT02592577",
      "title": "MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Carcinoma"
      ],
      "interventions": [
        {
          "name": "Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Adaptimmune",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2015-11",
      "completion_date": "2021-03-17",
      "has_results": false,
      "last_update_posted_date": "2025-12-09",
      "last_synced_at": "2026-10-19T04:44:21.672Z",
      "location_count": 14,
      "location_summary": "Duarte, California • Palo Alto, California • Miami, Florida + 11 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02592577"
    },
    {
      "nct_id": "NCT00570401",
      "title": "Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "dasatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 22,
      "start_date": "2006-06",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2016-01-22",
      "last_synced_at": "2026-10-19T04:44:21.672Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00570401"
    },
    {
      "nct_id": "NCT02309177",
      "title": "Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Pancreatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "nab-Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 114,
      "start_date": "2015-01-12",
      "completion_date": "2018-09-12",
      "has_results": false,
      "last_update_posted_date": "2019-05-31",
      "last_synced_at": "2026-10-19T04:44:21.672Z",
      "location_count": 15,
      "location_summary": "Sacramento, California • Santa Monica, California • New Haven, Connecticut + 11 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02309177"
    },
    {
      "nct_id": "NCT01242072",
      "title": "Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignancy",
        "Cancer",
        "Non Small Cell Lung Cancer",
        "Small Cell Lung Cancer",
        "Testicular Cancer",
        "Thymoma",
        "Ovarian Cancer",
        "Osteosarcoma"
      ],
      "interventions": [
        {
          "name": "palifosfamide-tris",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alaunos Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2010-12",
      "completion_date": "2012-07-16",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-19T04:44:21.672Z",
      "location_count": 4,
      "location_summary": "Indianapolis, Indiana • Lafayette, Indiana • Muncie, Indiana + 1 more",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Lafayette",
          "state": "Indiana"
        },
        {
          "city": "Muncie",
          "state": "Indiana"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01242072"
    },
    {
      "nct_id": "NCT06452277",
      "title": "A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Advanced Non-small Cell Lung Cancer, HER2 Mutation"
      ],
      "interventions": [
        {
          "name": "Sevabertinib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 444,
      "start_date": "2024-08-28",
      "completion_date": "2029-06-27",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-10-19T04:44:21.672Z",
      "location_count": 25,
      "location_summary": "Newport Beach, California • San Diego, California • San Francisco, California + 20 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06452277"
    },
    {
      "nct_id": "NCT03225664",
      "title": "Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Recurrent Lung Non-Small Cell Carcinoma",
        "Stage III Lung Cancer AJCC v8",
        "Stage IIIA Lung Cancer AJCC v8",
        "Stage IIIB Lung Cancer AJCC v8",
        "Stage IIIC Lung Cancer AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVB Lung Cancer AJCC v8",
        "Unresectable Lung Non-Small Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pharmacokinetic Study",
          "type": "OTHER"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2018-02-03",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-10-19T04:44:21.672Z",
      "location_count": 2,
      "location_summary": "New Haven, Connecticut • Houston, Texas",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03225664"
    }
  ]
}